Janux Therapeutics, Inc.
JANX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.1B
$18.03
▼ -3.99%
P/E
-10.99
Mkt Cap
$1.1B
52-Wk Range
$12.12–$35.34
52-Week Range
$12.12 - $35.34
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 21.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary TRACTr platform technology enabling tumor-specific T cell activation with potentially improved safety and efficacy profiles
- Dual-platform approach combining T cell engagers and immunomodulators addressing multiple mechanisms of cancer resistance
- Ability to leverage existing approved monoclonal antibodies in combination with TRACTr technology, reducing development risk and accelerating time-to-market
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Mild headwinds expected
Emerging player in Biotechnology
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+23.6% over 3m
Quality
Excellent
High-growth business (144% revenue growth, 69% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying JANX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.35 vs -$0.25 consensus (-39.3% surprise). Revenue of $10.3M vs $19.1M expected (-46.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-39.3%
Revenue trend · last 8Q
—
-100%
-100%
-100%
+12%
—
—
—
Q2 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$8.9M
$0
$0
$0
$10.0M
$7.9M
$3.7M
$10.3M
Margins · last 8Q
Gross
-31.8%
Operating
—
Profit
-214.0%
Wall Street consensus
7 analysts · 71% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
71%
Hold
14%
Sell
14%
Median Price Target
—
Latest: Wolfe Research · Aug 24, 2026
vs Industry
How JANX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related